Takeover rumors for biotech shares: BioNTech, Formycon, Cardiol Therapeutics and Novo Nordisk in focus

BioNTech and Formycon - Now on sale

BioNTech's shares have yet to gain momentum in 2024. The share price has fallen by 23% since January, and all hopes are pinned on the cancer-fighting pipeline that has been conjured up in various places. Business with COVID-19 vaccines is slowly running towards zero, meaning that the Mainz-based company will likely be in the red again this year. It is still completely unclear whether the emerging lawsuits in connection with the controversial vaccinations will come to the table at some point.

Behind the scenes, however, the Company is returning to its roots and is increasingly focusing on cancer drugs. The vision is to develop new types of mRNA vaccines against cancer that can be adapted to patients as required and may even provide a cure without surgical intervention. At EUR 82.90, the share price is not far off its low for the year of EUR 78.54, giving shareholders little reason to rejoice. The opinions of experts are also becoming increasingly skeptical, as only 8 out of 16 analysts on the Refinitiv Eikon platform are still positive and recommend the share as a "Buy", with an average price expectation of EUR 106, which still represents a potential upside of 27%.

Munich-based biosimilar specialist Formycon will hold a conference call tomorrow, April 25, to present its figures for 2023. Revenues rose from EUR 42.5 million to EUR 77.7 million in 2023. Despite a previously formulated negative EBITDA forecast, the Company reported a return to profitability with EUR 1.5 million. This was due to the pause in the development of FYB207 in 2023, resulting in unspent research funds. The EBITDA outlook for 2024 again indicates an intensification of investments in the biosimilar pipeline. Formycon aims to achieve sales of EUR 55 to 65 million, but research expenses will again have a strong negative impact on earnings of EUR -15 to -25 million. The share price fell back to EUR 39 yesterday and is thus only marginally above the mid-April low of EUR 37.65. The analyst consensus on the Refinitiv Eikon platform still sees a price target of EUR 101.75. This is surprisingly far from the current share price and will likely decrease with upcoming updates.

Cardiol Therapeutics - Plus 100% is just the beginning

We are moving from the rather consolidating stocks to a top shooter in the biotech sector. The Canadian company Cardiol Therapeutics Inc. has developed a promising drug candidate called CardiolRx™ in recent years. With its pharmaceutically manufactured, oral solution formulation, the Company is again making headlines because CardiolRx™ blocks the activation of the inflammasome signaling pathway.

After investing heavily in the product pipeline, CEO David Elsley summarizes 2023 and the aspirations for 2024 as follows: "Cardiol Therapeutics made significant progress in 2023 and early 2024 as we pursued our primary goal of providing new therapeutic options for patients with poorly treated heart disease." To support the ongoing clinical programs, Cardiol recently attended several scientific conferences where promising preclinical results were presented. In addition, the experts gained deep insights into the molecular and cellular mechanisms of action and benefits of the drug candidates. In February 2024, CardiolRx™ received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of pericarditis. With this tailwind, the Company is well positioned to achieve significant milestones in 2024 and further advance their goal helping people affected by underserved debilitating heart diseases.

Significant milestones in the MAvERIC, ARCHER, and CRD-38 programs are to be achieved in the current year, which should give the Company's valuation further momentum. The Cardiol share price has risen by almost 175% in the last 12 months without consolidating significantly. With sufficient cash, there is no need to refinance at this level. This means that there is no further dilution and shareholders can continue to benefit from the success of the programs. Cardiol is likely only at the beginning of a long-term revaluation.

Novo Nordisk - What the analysts say

Novo Nordisk continues to grow and expand its product portfolio. The Company is known worldwide for its innovations in the field of diabetes and obesity with leading products such as Wegovy and Ozempic. Now, the German Federal Cartel Office has approved the acquisition of Cardior Pharmaceuticals, leading the Danish pharmaceutical giant into a new era of cardiology research. With this strategic decision, Novo Nordisk underlines its recently emphasized ambition to expand its therapeutic offering beyond its core areas and further strengthens its position as an innovation leader in the healthcare sector. The Danish company also sees the opportunity to expand its portfolio with key therapeutic approaches in the field of cardiology.

The share has taken a pause in its upward trajectory in recent weeks. At a price of DKK 884 or EUR 118.9, the market capitalization now stands at EUR 518 billion. This makes Novo Nordisk one of the largest listed stocks in Europe. The analyst consensus on Refinitiv Eikon, with 17 recommendations out of 28 assessments, reflects high confidence in its future growth. The 12-month price targets have recently reached a consensus of DKK 945, which is around 6% higher than yesterday's price. Typically, experts may adjust their forecasts after new financial results, which are due to be released in a few days on May 2. It will be exciting to see whether the share price will then continue unabated or whether profit-taking will dominate the picture.

The major Biotech stocks are currently having a hard time. The impact of the COVID-19 pandemic, as observed in companies like BioNTech, is exerting pressure. Formycon has undergone several capital increases and must first digest the steep growth. While Novo Nordisk is growing through acquisitions, the Canadian company Cardiol Therapeutics is achieving growth through its own efforts.